LacC from streptococcus pneumoniae

Details LacC from streptococcus pneumoniae LacC from streptococcus pneumoniae

1998-11-04

2001-01-09

Duffy, Patricia A. (Department: 1645)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Transferase other than ribonuclease

C435S069700

Reexamination Certificate

active

06171840

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses. In particular, in these and in other regards, the invention relates to novel polynucleotides and polypeptides of the lacC/fruK (carbohydrate kinases) family, hereinafter referred to as “lacC”.
BACKGROUND OF THE INVENTION
The Streptococci make up a medically important genera of microbes known to cause several types of disease in humans, including, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid. Since its isolation more than 100 years ago,
Streptococcus pneumoniae
has been one of the more intensively studied microbes. For example, much of our early understanding that DNA is, in fact, the genetic material was predicated on the work of Griffith and of Avery, Macleod and McCarty using this microbe. Despite the vast amount of research with
Streptococcus pneumoniae
, many questions concerning the virulence of this microbe remain. It is particularly preferred to employ Streptococcal genes and gene products as targets for the development of antibiotics.
The frequency of
Streptococcus pneumoniae
infections has risen dramatically in the past 20 years. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate
Streptococcus pneumoniae
strains which are resistant to some or all of the standard antibiotics. This has created a demand for both new anti-microbial agents and diagnostic tests for this organism.
While certain Streptococcal factors associated with pathogenicity have been identified, e.g., capsule polysaccharides, peptidoglycans, pneumolysins, PspA Complement factor H binding component, autolysin, neuraminidase, peptide permeases, hydrogen peroxide, IgA1 protease, the list is certainly not complete. Moreover, very little is known concerning the temporal expression of such genes during infection and disease progression in a mammalian host. Discovering the sets of genes the bacterium is likely to be expressing at the different stages of infection, particularly when an infection is established, provides critical information for the screening and characterization of novel antibacterials which can interrupt pathogenesis. In addition to providing a fuller understanding of known proteins, such an approach will identify previously unrecognised targets.
The catabolic repertoires for using carbon and energy sources are very similar in all bacteria. Numerous as the catabolites might be, the fundamental biochemical mechanisms for their breakdown are few. These mechanisms include phosphorylation, phosphorolysis, keto-enol isomerizations, removal or addition of hydrogen pairs and aldol cleavage. Although the ways that bacteria can use to obtain energy are multiple, the inhibition of certain pathways could leave them with less possibilities for adaptation to the starvation conditions present during infection and therefore inhibitors of the proteins involved in catabolic pathways for sugars, polyols and carboxylates could prevent the bacterium from establishing or maintaining infection of the host and thereby have utility in anti-bacterial therapy.
Clearly, there is a need for factors, such as the novel compounds of the invention, that have a present benefit of being useful to screen compounds for antibiotic activity. Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease. There is also a need for identification and characterization of such factors and their antagonists and agonists which can play a role in preventing, ameliorating or correcting infections, dysfunctions or diseases.
The polypeptides of the invention have amino acid sequence homology to a known
Lactococcus lactis
lacC protein. Swiss-Prot accession number: P23391 tagatose-6-phosphate kinase (
Lactococcus lactis
); de Vos, W. M. et al., Characterization of the lactose-specific enzymes of the phosphotransferase system in
Lactolcoccus lactis
. J. Biol. Chem. 265 (36), 22554-22560 (1990); van Rooijen, R. J. et al., Molecular cloning, characterization, and nucleotide sequence of the tagatose 6-phosphate pathway gene cluster of the lactose operon of
Lactococcus lactis
. J. Biol. Chem. 266 (11), 7176-7181 (1991).
SUMMARY OF THE INVENTION
It is an object of the invention to provide polypeptides that have been identified as novel lacC polypeptides by homology between the amino acid sequence set out in Table 1 [SEQ ID NO:2] and a known amino acid sequence or sequences of other proteins such as
Lactococcus lactis
lacC protein.
It is a further object of the invention to provide polynucleotides that encode lacC polypeptides, particularly polynucleotides that encode the polypeptide herein designated lacC.
In a particularly preferred embodiment of the invention, the polynucleotide comprises a region encoding lacC polypeptides comprising the sequence set out in Table 1 [SEQ ID NO:1] which includes a full length gene, or a variant thereof.
In another particularly preferred embodiment of the invention, there is a novel lacC protein from
Streptococcus pneumoniae
comprising the amino acid sequence of Table 1 [SEQ ID NO:2], or a variant thereof.
In accordance with another aspect of the invention, there is provided an isolated nucleic acid molecule encoding a mature polypeptide expressible by the
Streptococcus pneumoniae
0100993 strain contained in the deposited strain.
As a further aspect of the invention, there are provided isolated nucleic acid molecules encoding lacC, particularly
Streptococcus pneumoniae
lacC, including mRNAs, cDNAs, genomic DNAs. Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.
In accordance with another aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization. Among the particularly preferred embodiments of the invention are naturally occurring allelic variants of lacC and polypeptides encoded thereby.
As another aspect of the invention, there are provided novel polypeptides of
Streptococcus pneumoniae
referred to herein as lacC as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.
Among the particularly preferred embodiments of the invention are variants of lacC polypeptide encoded by naturally occurring alleles of the lacC gene.
In a preferred embodiment of the invention, there are provided methods for producing the aforementioned lacC polypeptides.
In accordance with yet another aspect of the invention, there are provided inhibitors to such polypeptides, useful as antibacterial agents, including, for example, antibodies.
In accordance with certain preferred embodiments of the invention, there are provided products, compositions and methods for assessing lacC expression, treating disease, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid, assaying genetic variation, and administering a lacC polypeptide or polynucleotide to an organism to raise an immunological response against a bacteria, especially a
Streptococcus pneumoniae
bacteria.
In accordance with certain preferred embodiments of this and other aspects of the invention, there are provided polynucleotides that hybridize to lacC polynucleotide sequences, particularly under stringent conditions.
In certain preferred embodiments of the invention, there are provided antibodies against lacC polypep

Affiliated with

Also associated with

Rating

LacC from streptococcus pneumoniae does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with LacC from streptococcus pneumoniae, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and LacC from streptococcus pneumoniae will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2479004